Dental Care Clinics in Manlius, NY Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Gary L. Revercomb, Dmd Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 8076 Cazenovia Rd, Manlius, NY 13104 Phone: 315-682-8400 Fax: 315-682-2602 |
Jason D. Henderson, Dds Pc Dentist Medicare: Not Enrolled in Medicare Practice Location: 8179 Cazenovia Rd, Manlius, NY 13104 Phone: 315-685-2246 Fax: 315-682-3914 |
William H. Karp, D.d.s., Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 8179 Cazenovia Rd, Manlius, NY 13104 Phone: 315-682-2386 Fax: 315-682-3914 |
Fayetteville-manlius Oral Surgery, P.c Dentist - Oral and Maxillofacial Surgery Medicare: Not Enrolled in Medicare Practice Location: 8240 Cazenovia Rd Ste 60, Manlius, NY 13104 Phone: 315-692-0449 Fax: 315-692-6546 |
News Archive
Itamar Medical's EndoPAT systems in use around the world to diagnose cardiovascular disease
At the 2010 ACC conference held in Atlanta, GA, six new studies based on the PAT™ (Peripheral Arterial Tone) signal focused on assessing cardiovascular risk by measuring and improving endothelial health. Of those, two studies from Japan focused on assessing cardiovascular risk in both high and low risk patient populations.
Study sheds light on changes in young people's sexual practices
Published in the Journal of Adolescent Health, the study describes changes in young people's sexual practices using nationally-representative data from the National Surveys of Sexual Attitudes and Lifestyles, the largest scientific studies of sexual health and lifestyles in Britain.
Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention
Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.
U.S. District Court rules in favor of Cell Therapeutics to pursue all of its claims against The Lash Group
Cell Therapeutics, Inc. announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled that CTI should be allowed to pursue all of its claims against The Lash Group, sending the case back to the District Court for trial. CTI filed a complaint against The Lash Group, CTI's former third-party reimbursement consultant for CTI's product TRISENOX, in 2007 seeking $22.8 million in damages for expenses already incurred related to the investigation, defense and a settlement of claims by the U.S. government concerning Medicare reimbursement for TRISENOX and other business losses.
› Verified 5 days ago